Labs
Pre-crisis baseline — Function Health, May–June 2025. Right reference point for current monitoring on olanzapine + duloxetine + statin.
Summary
Severe baseline insulin resistance
Fasting insulin 57, glucose 105, A1c 5.8%. Olanzapine worsens exactly these markers — drug-duration choice matters.
Atherogenic dyslipidemia
Small dense LDL pattern B with LDL particle number 1789. Low HDL, high triglycerides. CAD history (quad bypass 2023) compounds the risk profile.
Reassuring at baseline
Liver (AST/ALT/Alk Phos/GGT), kidney (Cr 1.10), electrolytes (K 4.0), magnesium RBC 6.1, and thyroid all normal pre-crisis. Good news for olanzapine metabolism + QT risk and for duloxetine hepatic monitoring — worth a recheck on-drug.
Omega-3 status
EPA+DPA+DHA at 3.0% by wt — high relative risk of sudden cardiac death per Cleveland HeartLab cutoff. Omega-6:Omega-3 ratio 12.5:1. Vascepa is the modern Rx intervention.
Other historical context
ANA ≥1:1280 sustained across two draws, all specific autoantibodies negative, ESR + complement normal. GRAIL Galleri (June 2025): no cancer signal detected. DHEA-S low, testosterone low-normal.
Source PDFs
Source of truth. Hand these to the care team, not the summary. Function Health, ordered by Lauren Jefferis MD; processed by Quest + Cleveland HeartLab + GRAIL.
Important framing
This summary is Paul's lay reading for the family record. Not clinical advice, not a diagnosis. It exists to make sure nothing in the baseline gets overlooked by the team managing the current crisis.